<DOC>
	<DOCNO>NCT00403364</DOCNO>
	<brief_summary>To assess sequential treatment regimen well eradicates H. pylori triple drug regimen adult dyspepsia peptic ulcer disease .</brief_summary>
	<brief_title>Sequential Therapy Versus Triple Therapy Helicobacter Pylori Eradication : Placebo-Controlled Trial</brief_title>
	<detailed_description>Background : Antimicrobial resistance decrease eradication rate H. pylori worldwide . Objective : To assess sequential treatment regimen well eradicates H. pylori triple drug regimen adult dyspepsia peptic ulcer disease . Design : Placebo-controlled trial . Setting : Two Italian Hospitals September 2003 April 2006 . Patients : 300 dyspeptic peptic ulcer patient Measurements : 13C urea breath test , upper endoscopy , histology , rapid urease test , bacterial culture , antibiotic resistance assessment . Intervention : 10-day sequential regimen ( pantoprazole 40 mg , amoxicillin 1 g plus placebo first 5 day , follow pantoprazole 40 mg , clarithromycin 500 mg tinidazole 500 mg remain 5 day ) 150 patient standard 10-day therapy ( pantoprazole 40 mg , clarithromycin 500 mg , amoxicillin 1 g ) 150 patient . All drug give twice daily . Results : There 295 patient ( Intent treat ) 91 % ( 95 % CI : 86.5–95.7 ) successful eradication sequential therapy compare 78 % ( 95 % CI : 71.2–84.5 ) standard therapy ( difference : 13.3 % ; 95 % ) . The sequential therapy significantly effective patient clarithromycin resistant strain ( 88.9 % patient vs. 28.6 % ; P = 0.0034 ) . The incidence major minor side effect differ therapy group ( 17 % vs. 17 % ) . Limitations : Follow-up incomplete 4.6 % 2.7 % patient sequential standard therapy , respectively . The high efficacy sequential regimen confirm outside Italy . Conclusions : Sequential therapy superior conventional therapy eradication H. pylori significantly effective patient harbour clarithromycin resistant strain . The incidence side effect differ therapy group .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<criteria>Helicobacter pylorus infect patient &gt; 18 year previous H. pylorus eradication treatment ; Use proton pump inhibitor , H2receptor antagonists , bismuth preparation antibiotics previous 4 week ; Concomitant anticoagulant ketoconazole use , due potential interaction study medication ; ZollingerEllison syndrome ; Previous surgery esophagus and/or upper gastrointestinal tract ( exception appendectomy , polypectomy cholecystectomy ) ; Severe unstable cardiovascular , pulmonary , endocrine disease ; clinically significant renal hepatic disease dysfunction ; hematological disorder ; clinically significant medical condition could increase risk study participant ; malignant disease kind previous 5 year except successfully treat skin ( basal squamous cell ) cancer Barrett esophagus high grade dysplasia ; Drug medication abuse within past year ; Severe psychiatric neurological disorder ; Pregnant nursing woman sexually active woman child bear potential willing practice medically acceptable contraception ( oral contraceptive ; inject able/implantable mechanical device well vasectomy sexual partner ) entire duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Helicobacter pylorus infection</keyword>
	<keyword>Treatment</keyword>
	<keyword>Double blind placebo control trial</keyword>
</DOC>